June 21, 2023 — Fresenius Kabi, a leading provider of injectable medicines, announced today it has launched the diagnostic pharmaceutical agent, Sincalide for Injection, an authorized generic for Bracco Diagnostics Inc.’s Kinevac (Sincalide for Injection) product. The new product broadens Fresenius Kabi’s radiology portfolio and is available immediately in the United States.
Sincalide for Injection is a diagnostic aid used to help diagnose certain problems of the gallbladder and pancreas. Sincalide for Injection is also used to speed up the transit of a barium meal, a contrast agent, given in preparation for an X-ray examination of the intestines.1
"Fresenius Kabi is pleased to introduce Sincalide for Injection in the U.S. as our newest
first-to-market authorized generic, demonstrating our commitment to supporting the radiology community and strengthening the U.S. supply chain of care," said John Ducker, president and CEO of Fresenius Kabi USA. "Diagnostic pharmaceutical agents like Sincalide play a critical role in patient diagnosis, and Fresenius Kabi's addition of Sincalide provides health care facilities nationwide with new options to ensure timely patient care."
Fresenius Kabi Sincalide for Injection is the third product added to the company’s radiology portfolio, an area the company entered last year.
Sincalide for Injection is available to order direct from the company and U.S. wholesalers in 5 mcg single-dose vials. Fresenius Kabi Sincalide for Injection is preservative-free, and the container closure is not made with natural rubber latex.
Fresenius Kabi manufactures Sincalide for Injection in the United States, where the company has invested nearly $1 billion on an advanced manufacturing and distribution network dedicated to serving U.S. hospitals and health systems. To learn more about how Fresenius Kabi is strengthening America’s supply chain of care, please visit More in America.
For more information: www.fresenius-kabi.com/us
September 23, 2026 
